ARID5B and acute lymphoblastic leukemia: Our data show that the Ikaros binding to the ARID5B promoter is significantly increased upon CX-4945 treatment not only in Nalm6 and CEM cells (Fig. 5a), but also in primary B-/T-ALL cells (Fig. 5b).